Abstract:
The present disclosure generally relates to compositions and methods for the genetic modification of cells. In particular, the disclosure relates to CRISPR reagents and the use of such reagents.
Abstract:
The present disclosure generally relates to compositions and methods for improving the efficiency of homologous recombination. In particular, the disclosure relates to reagents and the use of such reagents.
Abstract:
The present disclosure generally relates to compositions and methods for genetic modification of cells. In particular, the disclosure relates to stabilized reagents for genome alteration ( e.g ., site specific nucleases), as well as stabilized reagents for non-genetic code altering modification ( e.g ., DNA methylation). Stabilization methods include storage of reagents at suitable temperatures, conversion to dry forms, and chemical modifications.
Abstract:
The present disclosure generally relates to compositions and methods for the genetic modification of cells. In particular, the disclosure relates to CRISPR reagents and the use of such reagents.
Abstract:
The present disclosure generally relates to compositions and methods for genetic modification of cells. In particular, the disclosure relates to stabilized reagents for genome alteration (e.g., site specific nucleases), as well as stabilized reagents for non-genetic code altering modification (e.g., DNA methylation). Stabilization methods include storage of reagents at suitable temperatures, conversion to dry forms, and chemical modifications.
Abstract:
The present disclosure generally relates to compositions and methods for improving the efficiency of homologous recombination. In particular, the disclosure relates to reagents and the use of such reagents.
Abstract:
The present disclosure generally relates to compositions and methods for the genetic modification of cells. In particular, the disclosure relates to CRISPR reagents and the use of such reagents.